Literature DB >> 21264750

Overt bone metastasis and bone marrow micrometastasis of early gastric cancer.

Hideyuki Ubukata1, Gyou Motohashi, Takanobu Tabuchi, Hiroyuki Nagata, Satoru Konishi, Takafumi Tabuchi.   

Abstract

Recently we encountered two cases of early gastric cancer (EGC) with bone metastasis after surgery. As they were not accompanied by overt liver, lung, or peritoneal metastasis, we examined the clinical significance of bone metastasis in EGC and its mechanisms by a review of the literature. We found only 10 cases of EGC complicated with overt bone metastasis in the English literature, so we also examined the Japanese reports of such cases. The main histologic type of cases of bone metastasis from EGC was the diffuse type, and there were long intervals between surgery and overt bone metastasis. One reason for such long intervals may have been the tumor dormancy. Two types of dormancy, dynamic and static, and two types of postoperative overt metastases, that of micrometastatic origin (normograde metastatic process) and that of bone marrow origin (retrograde metastatic process), were considered. We speculated that there may be specific routes by which the cancer cells infiltrate the bone marrow directly from EGC or lymph node metastasis. The procedures for diagnosing bone micrometastasis using monoclonal antibodies have recently been improved, but their accuracy rates are still not universally accepted. New, more reliable examinations are required to improve the survival rates of EGC.

Entities:  

Mesh:

Year:  2011        PMID: 21264750     DOI: 10.1007/s00595-010-4389-7

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  44 in total

Review 1.  Last-intercalated node and direct lymphatic drainage into the thoracic duct from the thoracoabdominal viscera.

Authors:  Gen Murakami; Masato Abe; Tomio Abe
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2002-03

2.  Prognostic significance of bone marrow micrometastases in patients with gastric cancer.

Authors:  K W Jauch; M M Heiss; U Gruetzner; I Funke; K Pantel; R Babic; H J Eissner; G Riethmueller; F W Schildberg
Journal:  J Clin Oncol       Date:  1996-06       Impact factor: 44.544

3.  The accuracy of sentinel node mapping according to T stage in patients with gastric cancer.

Authors:  Igor Rabin; Bar Chikman; Ron Lavy; Natan Poluksht; Zvi Halpern; Ilan Wassermann; Ruth Gold-Deutch; Judith Sandbank; Ariel Halevy
Journal:  Gastric Cancer       Date:  2010-04-07       Impact factor: 7.370

4.  CT appearance of bone metastases detected with FDG PET as part of the same PET/CT examination.

Authors:  Yuji Nakamoto; Christian Cohade; Mitsuaki Tatsumi; Dima Hammoud; Richard L Wahl
Journal:  Radiology       Date:  2005-11       Impact factor: 11.105

5.  The role of the sentinel lymph node in gastrointestinal cancer.

Authors:  Y Kitagawa; H Fujii; M Mukai; T Kubota; N Ando; M Watanabe; M Ohgami; Y Otani; S Ozawa; H Hasegawa; T Furukawa; K Kumai; T Ikeda; T Nakahara; A Kubo; M Kitajima
Journal:  Surg Clin North Am       Date:  2000-12       Impact factor: 2.741

Review 6.  Micrometastatic bone marrow involvement: detection and prognostic significance.

Authors:  S Braun; K Pantel
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

7.  A case of bone marrow recurrence from gastric carcinoma after a nine-year disease-free interval.

Authors:  N Noda; T Sano; K Shirao; H Ono; H Katai; M Sasako; K Maruyama
Journal:  Jpn J Clin Oncol       Date:  1996-12       Impact factor: 3.019

8.  Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression.

Authors:  L Holmgren; M S O'Reilly; J Folkman
Journal:  Nat Med       Date:  1995-02       Impact factor: 53.440

9.  Two cases of histopathologically advanced (stage IV) early gastric cancers.

Authors:  M Shiomi; T Kamisako; I Yutani; M Kudo; H Shigeoka; A Tanaka; K Okuno; M Yasutomi
Journal:  Tumori       Date:  2001 May-Jun

Review 10.  Gastric cancer with bone marrow invasion at presentation: case-report and review of the literature.

Authors:  D Crivellari; A Carbone; R Sigon; A Buonadonna; R Cannizzaro; R Sorio; C Rossi; S Monfardini
Journal:  Tumori       Date:  1995 Jan-Feb
View more
  7 in total

1.  Osteoplastic bone metastasis in esophageal squamous cell cancer: report of a case.

Authors:  Yasuaki Nakajima; Shunsuke Ohta; Takuya Okada; Yutaka Miyawaki; Akihiro Hoshino; Tomoyoshi Suzuki; Kenro Kawada; Tetsuro Nishikage; Kagami Nagai; Keisuke Ae; Hiroshi Kawachi; Tatsuyuki Kawano
Journal:  Surg Today       Date:  2011-11-18       Impact factor: 2.549

2.  Factors associated with early recurrence after curative surgery for gastric cancer.

Authors:  Wei-Ming Kang; Qing-Bin Meng; Jian-Chun Yu; Zhi-Qiang Ma; Zhi-Tian Li
Journal:  World J Gastroenterol       Date:  2015-05-21       Impact factor: 5.742

3.  Bone recurrence after curative resection of gastric cancer.

Authors:  Jae Myung Park; Kyo Young Song; Joo Hyun O; Won Chul Kim; Myung-Gyu Choi; Cho Hyun Park
Journal:  Gastric Cancer       Date:  2012-09-08       Impact factor: 7.370

4.  Compressive myeloradiculopathy from bony metastasis as the initial presentation of poorly differentiated adenocarcinoma stomach - a case report.

Authors:  Aneesh Basheer; Jolly Daniel; Somanath Padhi
Journal:  Australas Med J       Date:  2013-10-31

5.  Bone Metastasis From Gastric Adenocarcinoma-What Are the Risk Factors and Associated Survival? A Large Comprehensive Population-Based Cohort Study.

Authors:  Lei Huang; Yajie Zhao; Yan Shi; Weiguo Hu; Jun Zhang
Journal:  Front Oncol       Date:  2022-03-25       Impact factor: 6.244

Review 6.  Tumor-Derived Exosomes Modulate Primary Site Tumor Metastasis.

Authors:  Suwen Bai; Zunyun Wang; Minghua Wang; Junai Li; Yuan Wei; Ruihuan Xu; Juan Du
Journal:  Front Cell Dev Biol       Date:  2022-03-02

Review 7.  Tumor Microenvironment, Clinical Features, and Advances in Therapy for Bone Metastasis in Gastric Cancer.

Authors:  Pengcheng Sun; Samuel O Antwi; Kurt Sartorius; Xiao Zheng; Xiaodong Li
Journal:  Cancers (Basel)       Date:  2022-10-06       Impact factor: 6.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.